Source comparison
CJC-1295 Half-Life: DAC vs Non-DAC Comparison
The table below compares the two CJC-1295 variants across key pharmacokinetic and practical parameters. Understanding these differences is essential for selecting the appropriate peptide for specific research applications. Plasma Half-Life 6–8 days <30 minutes
This comparison does not assign a generated winner or score.
- The table below compares the two CJC-1295 variants across key pharmacokinetic and practical parameters. Understanding these differences is essential for selecting the appropriate peptide for specific research applications.
- Plasma Half-Life
- 6–8 days
- <30 minutes
- DAC extends circulation by >200× through albumin binding
- Biological Half-Life (GH Elevation)
- 6+ days continuous
- 2–3 hours per dose
- Non-DAC mimics natural pulsatile GH release
- Typical Dosing Frequency
- Once or twice weekly
- 2–3 times daily
- DAC reduces administration burden but removes pulsatility
- Dose Per Administration
- 1–2 mg per injection
- 100–200 mcg per injection
- Weekly DAC dose ~7× higher due to sustained release
- Time to Steady State
- 21–28 days (3–4 injections)
- Immediate (no accumulation)
- DAC requires loading period; non-DAC reaches effect within hours
- Receptor Desensitization Risk
- Moderate to high (continuous elevation)
- Low (pulsatile matches physiology)
- Prolonged GH elevation may reduce receptor sensitivity over time
- Reconstituted Stability (2–8°C)
- 28+ days
- 14–21 days
- Albumin binding stabilizes DAC version in solution
- Primary Research Use Case
- Sustained anabolic stimulus, convenience dosing
- Mimicking natural GH pulsatility, performance timing
- Choose based on desired GH secretion pattern, not just convenience